1) Malech HL, Maples PB, Whiting-Theobald N, et al:Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 94:12133-12138, 1997
2) Malech HL:Use of serum-free medium with fibronectin fragment enhanced transduction in a system of gas permeable plastic containers to achieve high levels of retrovirus transduction at clinical scale. Stem Cells 18:155-156, 2000
3) Hacein-Bey-Abina S, Le Deist F, Carlier F, et al:Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:1185-1193, 2002
4) Aiuti A, Slavin S, Aker M, et al:Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:2410-2413, 2002
5) Gasper HB, Bjorkegren E, Paresley K, et al:Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 14:505-513, 2006
6) Ott MG, Schmidt M, Schwarzwaelder K, et al:Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:401-409, 2006
7) Hacein-Bey-Abina S, Von Calle C, Schmidt M, et al:LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419, 2003